Connor, Clark & Lunn Investment Management (CC&L)’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-170,211
| Closed | -$3.94M | – | 1563 |
|
|
2023
Q1 | $3.94M | Sell |
170,211
-65,605
| -28% | -$1.52M | 0.02% | 415 |
|
|
2022
Q4 | $6.18M | Sell |
235,816
-51,468
| -18% | -$1.35M | 0.04% | 311 |
|
|
2022
Q3 | $5.65M | Buy |
287,284
+166,342
| +138% | +$3.27M | 0.04% | 301 |
|
|
2022
Q2 | $2.12M | Buy |
120,942
+94,795
| +363% | +$1.66M | 0.01% | 459 |
|
|
2022
Q1 | $428K | Buy |
26,147
+5,881
| +29% | +$96.3K | ﹤0.01% | 810 |
|
|
2021
Q4 | $331K | Buy |
+20,266
| New | +$331K | ﹤0.01% | 872 |
|
|
2020
Q2 | – | Sell |
-7,822
| Closed | -$107K | – | 1210 |
|
|
2020
Q1 | $107K | Sell |
7,822
-29,814
| -79% | -$408K | ﹤0.01% | 926 |
|
|
2019
Q4 | $222K | Buy |
37,636
+28,937
| +333% | +$171K | ﹤0.01% | 820 |
|
|
2019
Q3 | $46K | Sell |
8,699
-280
| -3% | -$1.48K | ﹤0.01% | 936 |
|
|
2019
Q2 | $69K | Buy |
8,979
+2,264
| +34% | +$17.4K | ﹤0.01% | 960 |
|
|
2019
Q1 | $134K | Buy |
+6,715
| New | +$134K | ﹤0.01% | 853 |
|